BioCentury | Dec 30, 2016
Emerging Company Profile

Mining for substitutions

...in the clinic for infectious disease that are not conventional antibiotics. Pergamum AB is developing DPK-060...
BioCentury | Dec 24, 2012
Clinical News

DPK-060: Phase II data

...69 patients with acute external otitis caused by bacterial or fungal pathogens showed that thrice-daily DPK-060...
...7-10 days was safe and well tolerated for topical treatment in the outer auditory channel. DPK-060...
...rating scale used. Pergamum said it will begin seeking a partner for DPK-060 in 2013. DPK-060...
BioCentury | Jan 23, 2012
Clinical News

DPK-060: Phase II started

...Pergamum began a double-blind, placebo-controlled, Swedish Phase II trial to evaluate thrice-daily DPK-060 2% ear drops...
...acute external otitis caused by bacterial or fungal pathogens. Pergamum AB , Stockholm, Sweden Product: DPK-060...
BioCentury | Mar 7, 2011
Company News

Pergamum, Karolinska Development dermatology, musculoskeletal news

Karolinska disclosed in its 2010 earnings that in December, Pergamum acquired full ownership of Lipopeptide AB, PharmaSurgics AB and DermaGen AB. In 2009, Karolinska combined its portfolio companies DermaGen, Lipopeptide, Omnio Healer AB, BioCis Pharma...
BioCentury | Dec 7, 2009
Clinical News

DPK-060: Phase I/IIa data

...the double-blind, placebo-controlled portion of a Phase I/IIa trial in 41 patients showed that twice-daily DPK-060...
...endpoint of significantly reducing microbial density in eczematous lesions vs. placebo at day 14 (p=0.012). DPK-060...
...AB, a unit of Pergamum (see BioCentury, Sept. 14). Pergamum AB , Stockholm, Sweden Product: DPK-060...
BioCentury | Sep 14, 2009
Company News

Karolinska Development dermatology, musculoskeletal news

...an emulsion cream formulation of cis-urocanic acid in Ph II testing for atopic dermatitis; DermaGen's DPK-060...
Items per page:
1 - 6 of 6